Summary In this study we compared the diagnostic utility of: (1) neuron-specific enolase (NSE); (2) squamous cell carcinoma antigen (SCC); (3) carcinoembryonic antigen (CEA); and (4) cytokeratin markers (CYFRA 21-1, TPA, TPM, TPS) in patients with small-cell lung cancer (SCLC) (21 cases) and non-small-cell lung cancer (94 cases). For comparison we also studied 66 patients with benign lung diseases and nine with pleural mesothelioma. NSE levels in SCLC patients were significantly higher than those in all the other groups studied. No significant variations were found among the SCC levels in all groups. CEA levels in patients with adenocarcinoma were significantly higher than those in all other groups studied. CYFRA 21-1 serum levels significantly increased in patients with squamous cell carcinoma and mesothelioma, while TPA, TPS and TPM increased in patients with lung cancer irrespective of the histological type. In patients with SCLC, high levels of all markers except SCC were found when the disease was extensive. In patients with non-SCLC, the highest levels of all tumour markers were usually found in those with advanced disease, although CYFRA 21-1 gave a sensitivity of 44% when a specificity of 95% was fixed in stage I non-SCLC patients. An analysis of receiver operating characteristic curves revealed that the highest diagnostic accuracies in distinguishing benign from malignant lung diseases were achieved with TPM (81%), CYFRA 21-1 (72%), CEA (78%) or TPA (78%) when using cut-off values of 46 U 1-', 3.0 g 1-g', 2.0 ;g l-l and 75 U l-1' respectively. When all patients were considered, the combined evaluation of more than one marker did not significantly improve the results obtained with TPM alone. However, taking into consideration the fact that CYFRA 21-1 is the most sensitive index of early lung tumours and that its combined determination with TPM did not worsen the overall sensitivity and specificity of the latter, the combined use of these two markers may be suggested as a useful took for the diagnosis of lung tumours.
Lung cancer, the most frequent malignant tumour in industrialised countries after breast and colorectal cancer, is classified as small-cell lung cancer (SCLC), squamous cell carcinoma, primary adenocarcinoma and large-cell carcinoma. The neuroendocrine properties of SCLC give it specific biological and clinical features. Since from a prognostic and therapeutic viewpoint squamous cell carcinoma, primary adenocarcinoma and large-cell carcinoma behave similarly, they are all pooled into a single group named non-small-cell lung cancer (Carney and De Leij, 1988) .
In order to improve the clinical approach to lung cancer patients, several serum tumour markers have been studied, and in this context recent interest has been focused on the role of serum cytokeratins (Pujol et al., 1993; Stieber et al., 1993a,b; Ebert et al., 1994; Plebani et al., 1994; van der Gaast et al., 1994) , which make up the intermediate filament cytoskeleton within epithelial cells, and consist of at least 19 different polypeptides, numbered 1 to 19 (Lazarides, 1980; Moll et al., 1982) .
Cytokeratins can be detected both in normal as well as in malignant tissues of epithelial origin (Moll et al., 1982; Broers et al., 1988) , and each polypeptide seems to be typical of certain types of epithelial differentiation (Moll et al., 1982; Sun et al., 1983) .
Tissue polypeptide antigen (TPA) detects mainly cytokeratins 8 and 19 and, to a very small degree, cytokeratin 18, while tissue polypeptide-specific antigen (TPS) mainly detects cytokeratin 18 and, to a small extent, cytokeratins 8 and 19 (Bodenmuller, 1993) . TPA is recognised by polyclonal antisera against cytokeratins 8, 18 and 19. To enhance the sensitivity and specificity of TPA assay, a new assay is now available, which is based on the use of three monoclonal antibodies directed against cytokeratins 8, 18 and 19, allowing detection of TPM antigen (Gion et al., 1994) . CYFRA 21-1 detects a fragment of cytokeratin 19 (Pujol et al., 1993) . Of these markers, TPA and CYFRA 21-1 seem to be the most sensitive and specific serum markers of lung cancer (Mizushima et al., 1991; Stieber et al., 1993a; Ebert et al., 1994) .
The neuroendocrine marker serum neuron-specific enolase (NSE) is helpful in the diagnosis and monitoring of SCLC (Harding et al., 1990; Jorgensen et al., 1992; Bergman et al., 1993) . Squamous cell carcinoma antigen (SCC) and carcinoembryonic antigen (CEA) have been extensively studied in patients with lung cancer; however, their sensitivity and specificity have usually been reported as low (Mizushima et al., 1991; Jarvisalo et al., 1993; Ebert et al., 1994) . Few reports deal with a combined evaluation of various tumour markers in lung cancer diagnosis (Mizushima et al., 1991; Jarvisalo et al., 1993; Stieber et al., 1993a; Ebert et al., 1994) .
The aims of this study were therefore to: (1) assess the behaviour of CYFRA 21-1, TPA, TPS, TPM, NSE, SCC and CEA in patients with SCLC and with non-small-cell lung cancer; (2) evaluate whether their combined determination enhances their diagnostic accuracy; and (3) assess whether there is any correlation between tumour stage and serum marker levels.
Materials and nethods
We studied a total of 190 subjects: 66 (42 males, 24 females, age range 19-70) had benign lung disease (BLD, . In contrast, the NSE levels in patients with SCLC were signifiantly higher than those in all the other groups studied. No signiicant variations were found among the SCC lvels of all groups. Table I illustrates the sensitivity of the seven serum markers studied when a specificity of 95% was fixed; the corresponding cut-off values are also reported. Figure 2 reports the sensitivity values, for a fixed specificity of 95%, of all markers in relation to tumour stage and histological type. For non-small-cell lung cancer the TNM classification was considered, while SCLC patients were subdivided on the basis of a limited or extensive disease. Figure 3 illustrates the ROC curves of each marker in differentiating benign from malignant lung diseases. An analysis of the ROC curves revealed that the higher diagnostic accuraces were achieved with TPM (81%, sensitivity 79% and specificity 84%), CYFRA 21-1 (72%, sensitivity 64% and speciiity 86%), CEA (78%, sensitivity 89% and specificity 56%) and TPA (78%, sensitivity 82% and specificity 71%) when using cut-off values of 46U1-', 3.0 sgl ', 2.Opgl-' and 75U1-' respectively. Table IV reports sensitivity and specificity with the combined evaluation of CYFRA 21-1, CEA, TPA and TPM. The highest sensitivity was obtained when three markers were combined. This increase in sensitivity was achieved at the cost of specificity. The best specificity, with an overall satisfactory sensitivity, was obtained with the combination of CYFRA 21-1 and TPM.
All the cytokeratins we studied exhibited a sinilar pattern, being significantly higher in patients with any histologcal lung cancer type than in patients with benign lung diseases. As with the other cytokeratns, CYFRA 21-1 was not related to the histological tumour type. In contrast, CEA and NSE levels were higher in patients with adenocarcinoma and with SCLC respectively, than in patients with other lung tumours. Patients with squamous cell carcinoma had the highest SCC values, although this difference was not of statistical signifi. When, however, a specificity of 95% was fixed, CYFRA 21-1, TPM and TPA in that order were found to be the most sensitive index in diagnosing hmg cancer, confirming for CYFRA 21-1 the obsrvations made by Stieber et al. (1993a) and Ebert et al. (1994) . All the other markers had sensitivities below 35% and therefore could not be considred singly as useful markers of different types of lung cancer. One of the main drawbacks of serm tumour markers is that the highest levels are usually found when disease is-at an advanced stage. We therefore investigated whether there is any correlation between the markers studied and tumour stage. Patients with SCLC were subdivided into two groups on the basis of (1) tumour confined to one hemithorax with or without mediastinal lymph node involvement (limited) or (2) tumour spread beyond this limit (extensive). Non-smallcell lung cancers were staged according to the TNM classification. In SCLC, all markers but SCC reached high levels in about 50% of patients with an extensive disease, while patients with limited SCLC were discriminated from patients with benign lung diseases in a very small percentage of cases. Therefore, none of the tumour markers studied can be considered an early itor of this type of hlug cancer. In conclusion, the use of tumour markers can be of some help in the diagnosis of small-cell and non-small-cell lung cancer; cytokeratins in serum are increased independently of histological tumour type. Overall, the most sensitive and specific indices of lung cancer are TPM and CYFRA 21-1; their combined use is to be recommended, since the latter was found in 44% of cases of early tumour, while the former was found mainly in patients with advanced lung tumours.
